Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
Combining two cancer drugs works much better for prostate cancer patients carrying BRCA2 mutations, pointing toward personalized treatment strategies.
This Phase II trial (n=61) of olaparib plus durvalumab in HRR-unselected mCRPC demonstrated modest overall efficacy but markedly improved outcomes in BRCA2-variant patients (rPFS 13.2 vs 4.8 months). Integrated ctDNA and peripheral immune profiling identified IL1R2 expression as a candidate response biomarker, supporting molecular selection strategies for PARP-immunotherapy combinations.
What the study was
- Study design
- Phase II single-arm open-label trial
- Population
- Men with metastatic castration-resistant prostate cancer (mCRPC), previously treated with abiraterone and/or enzalutamide
- Sample size
- 61
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal for Immunotherapy of Cancer
Why it surfaced
Phase II RCT data for PARP+IO combination in mCRPC with molecular biomarker discovery (ctDNA + IL1R2); BRCA2 subgroup finding clinically actionable. Score capped at 7 due to modest overall efficacy and single-arm design without randomized comparator.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.